PLoS ONE (Jan 2022)

Serotype-specific effectiveness against pneumococcal carriage and serotype replacement after ten-valent Pneumococcal Conjugate Vaccine (PCV10) introduction in Pakistan.

  • Muhammad Imran Nisar,
  • Fyezah Jehan,
  • Shahira Shahid,
  • Sheraz Ahmed,
  • Sadia Shakoor,
  • Furqan Kabir,
  • Aneeta Hotwani,
  • Sahrish Muneer,
  • Farah Khalid,
  • Sajid Muhammad,
  • Benjamin M Althouse,
  • Hao Hu,
  • Cynthia G Whitney,
  • Asad Ali,
  • Anita K M Zaidi,
  • Saad B Omer,
  • Najeeha Iqbal

DOI
https://doi.org/10.1371/journal.pone.0262466
Journal volume & issue
Vol. 17, no. 1
p. e0262466

Abstract

Read online

ObjectivePakistan was one of the first South-Asian countries to introduce the ten-valent pneumococcal conjugate vaccine (PCV10) at the national level, using a 3+0 schedule without catchup, in 2013.MethodsFrom 2014-18, fifteen children ResultsPneumococcus was detected in 2370/3140 (75%) children. Vaccine type (VT) and non-vaccine type (NVT) serotypes were carried by 379 and 1990 children. There was a significant decline in VT carriage (by 40.3%, p-value ConclusionThe emergence of NVT serotypes, primarily 19A replacing VT serotypes in this rural community, necessitates continuous monitoring of serotypes in the carriage and invasive disease to evaluate the utility of existing vaccine formulations.